Precision BioSciences Shuffles Leadership Ahead of Key Clinical Milestones
Event summary
- Alex Kelly promoted from CFO to Chief Operating Officer effective August 1, 2026.
- Naresh Tanna moves from VP Investor Relations to CFO role.
- Two new physician leaders hired to support clinical programs PBGENE-HBV and PBGENE-DMD.
- Cassie Gorsuch, PhD, expands role to lead all research functions including translational sciences.
The big picture
Precision BioSciences is restructuring its senior leadership to support the advancement of its clinical-stage gene editing programs through critical milestones. This move reflects a strategic shift toward operational excellence as the company prepares to generate more clinical data from its key studies. The biotech industry continues to face intense competition, making efficient program execution crucial for maintaining investor confidence and market position.
What we're watching
- Execution Risk
- How the leadership transition will impact the pace of clinical development for PBGENE-HBV and PBGENE-DMD programs.
- Operational Efficiency
- Whether Alex Kelly's move to COO can streamline customer-facing functions during this critical phase.
- Clinical Milestones
- The pace at which Precision BioSciences advances its ELIMINATE-B and FUNCTION-DMD studies under the new leadership structure.
Related topics